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CYTOTOXIC ACTIVITY OF IMMUNE CELLS FOLLOWING 
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Aim: To study the effects of xenogeneic cancer vaccine (XCV) developed on the basis of nervous tissue antigen from rat embryo 
of late gestation period and protein-containing metabolite of Bacillus subtilis with molecular weight of 70 kDa, on specific and 
unspecific antitumor reactions of cellular and humoral chains of immune system, and to analyze possible mechanisms of its 
antimetastatic action. Materials and Methods: XCV was administered triply with 3-day intervals after surgical removal of experi-
mental melanoma В-16 in C57Bl/6 mice. Cytotoxic activity (CTA) of splenocytes against target cells К-562 as well as CTA 
of splenocytes, peritoneal macrophages (PM) and blood serum against melanoma В-16 target cells were determined using МТТ 
test. The content of circulating immune complexes (CIC) in blood serum was evaluated by precipitation reaction. Results: Immu-
nologic effects of XCV vaccination in experimental animals with surgically removed melanoma B-16 in comparison with similarly 
treated unvaccinated mice were as follows: prevention of medium molecular weight CIC accumulation in blood serum during all 
observation period, significant increase (р < 0.05) of CTA of effectors of unspecific antitumor immunity (natural killer cells — 
NK — by 25.5 ± 1.7 vs 12.5 ± 5.4%, and PM — by 37.3 ± 0.6 vs 32.0 ± 0.9%, respectively) at 37th day after the surgery, and also 
preservation of functional activity of specific cytotoxic lymphocytes at the level of intact control. Conclusion: The results of the study 
allow propose that antimetastatic effect of XCV vaccination could be based on increased CTA of NK and PM, and preservation 
of CTL functional activity at late terms after surgical removal of B-16 primary tumors.
Key Words: xenogeneic cancer vaccine, melanoma В-16, natural killer cells, macrophages, cytotoxic lymphocytes, cytotoxic 
activity, antimetastatic activity.
Skin melanoma still belongs to the most aggressive 
cancer types, and its incidence is constantly rising 
worldwide. In 2013, in Ukraine the number of newly 
registered melanoma cases was 3278, and the total 
number of melanoma patients under observation 
was 25 754. After development of distant metastases 
an average life expectancy of melanoma patients 
ranges from 6 to 9 months, and 5-year survival rate 
is lower than 5% [1].
The main method of melanoma treatment is its 
surgical removal while chemotherapy shows low ef-
ficacy. Therefore, the search of high effective means 
for treatment of melanoma patients remains an ac-
tual task. Numerous experimental and clinical data 
evidence on possibility of effective use of immuno-
therapeutical methods for therapy of melanoma [2–6], 
in particular, active specific immunotherapy with the 
use of cancer vaccines [7–9]. The use of vaccines 
prepared on the basis of xenogeneic tumor cells for 
melanoma therapy is of special interest because such 
approach allows significantly increase immunogene-
city of cancer vaccine. An induction of specific cellular 
and humoral immune response against self tumor 
antigens in the case of use of xenogeneic vaccines 
relies on high homology between tumor-associated 
antigens of man and animals [10–12], in particular 
those of man and mouse [13, 14]. The presence 
of such homology was utilized in some experimental 
and clinical stu dies where for melanoma treatment 
tumor antigens of mouse were used as xenogeneic 
ones in humans, and vice versa [15, 16]. In particular, 
xenovaccination with the use of transplantable human 
melanoma SK-MEL-28 cells or primary human mela-
noma cell culture performed at prophylactic regimen 
with following removal of primary tumor node, resulted 
in significant suppression of syngeneic melanoma 
В-16 in mice and reduced lung metastasis. Such vac-
cination induced an appearance of specific cytotoxic 
splenocytes, cytotoxic activity (CTA) of which was 
preserved for 12 weeks [17, 18]. In other experimental 
studies, it has been shown that immunization of mice 
with glycoproteins gp75 and gp100 associated with 
human melanoma is capable to prevent tumor deve-
lopment [19, 20].
At present time, there are the reports on effective 
therapy of melanoma patients with xenogeneic poly-
antigenic cancer vaccines composed from melanoma 
and carcinoma antigens of mouse. Clinical studies have 
demonstrated an efficacy of such vaccine in the therapy 
of patients with melanoma or colorectal cancer [21–23].
In the Department of Biotherapeutical Means Con-
struction of R.E. Kavetsky Institute of Experimental 
Pathology, Oncology and Radiobiology of the NAS 
of Ukraine (IEPOR NASU) there has been developed 
a xenogeneic cancer vaccine (XCV) on the basis of ner-
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vous tissue antigen from rat embryo of late gestation 
period and protein-containing metabolite of Bacillus 
subtilis with molecular weight of 70 kDa [24]. In ex-
perimental melanoma В-16 model there has been 
shown that such vaccine is highly effective only in the 
case of surgical removal of the primary tumor node, 
and then metastasis inhibition index was higher than 
95% [25]. Immunologic mechanisms of antitumor 
and antimetastatic activity of the vaccine remained 
unstudied. Therefore, in present work we aimed 
to evaluate an influence of oncofetal XCV on some 
indexes of anticancer immunity and to study possible 
mechanism of antimetastatic action of the vaccine 
in mice with surgically removed В-16 melanoma.
MATERIALS AND METHODS
The study has been carried out on female 
C57Bl/6 mice 2.5 months old weighting 18–19 g, 
bred in the vivarium of IEPOR NASU. The use and care 
of experimental animals have been performed in ac-
cordance with standard international rules on biologic 
ethics and was approved by Institutional Animal Care 
and Use Committee [26, 27].
As experimental transplantable tumor model, 
mouse melanoma B-16 cells obtained from National 
Bank of Human and Animal Tissues of IEPOR NASU, 
were used. This strain is maintained by passages 
in C57Bl/6 mice. For transplantation melanoma cell 
suspension was prepared by primary tumor trypsiniza-
tion according to the method [28]. Tumor cells were 
routinely transplanted in a foot of the right hind leg 
(2.5•105 cells/mouse in a volume of 0.05 ml). At 18th 
day after tumor transplantation when the primary tu-
mor reached a diameter of 0.8 ± 0.2 cm, the surgical 
removal of a tumor-bearing foot was performed under 
ethaminal sodium narcosis (40 mg/kg). Three days 
later the treatment with XCV was initiated. Vaccine 
([С] = 0.3 mg/ml) was injected subcutaneously, triply 
with 3 days intervals by 0.3 ml/mouse ([С] = 0.09 mg/
animal per 1 injection) with following revaccination with 
7 days interval. The control groups were composed from 
intact animals and unvaccinated animals with melanoma 
treated by surgical removal of В-16 melanoma.
Immunological examination of the animals was per-
formed at 4th, 18th, 32nd and 37th days after the surgery 
(at 22nd, 36th, 51st and 56th days after tumor transplanta-
tion, respectively). In control and experimental groups 
of animals the indexes of cellular and humoral chains 
of anticancer immunity were analyzed.
The indexes of weight and cellularity of immu-
nocompetent organs were determined by standard 
method of supravital staining with trypan blue [29].
Cytotoxic activity (CTA) of blood serum (SB) 
and effector cells (EC) were determined by  МТТ-test. 
Spleen lymphocytes (natural killer cells — NK), 
cytotoxic Т-lymphocytes (CTL) and peritoneal macro-
phages (PM) were used as EC. K-562 cells were used 
as target cells (TC) for determination of unspecific 
NK cell cytotoxicity, while melanoma В-16 cells were 
used as TC for determination of specific cytotoxicity 
of CTL and PM [30]. In brief, TC were placed in  96-well 
plate by 2•104 cells/well in a volume of 0.1 ml, and 
EC were placed by 1•105 cells/well in a volume 
of 0.1 ml at the TC/EC ratio of 1 : 5. Plates were incu-
bated for 18 h in the 100% humidity atmosphere with 
5% СО2 at 37 °С. Then 0.01 ml of МТТ solution per 
well concentration 5 mg/ml (“Sigma”) was added, 
and incubation continued for 2 h. Then the plates 
were centrifuged at 1500 g for 15 min, twice washed 
with physiologic solution, and DMSO was added into 
the well (by 0.14 ml). Optical density was measured 
at λ = 545 nm vs λ = 630 nm with the use of micro 
ELISA reader (StatFax-2100, USA). Each sample was 
measured in triplicate. CTA index (CTAI, %) for each 
EC type was calculated by the formula:
CTAIec = [1 – (ODеc+tc – ODеc)/(ODtc – ODblank)] • 100%,
 where ODеc — optical density in the samples with EC; 
ODtc — optical density in the samples with TC; ODеc+tc — 
optical density in experimental series; ODblank– optical 
density in the control well with cultivation medium only.
The level of circulating immune complexes 
(CIC) in SB of mice was determined in precipitation 
reaction: high molecular weight CIC with the use 
of 3% polyethylene glycol (PEG), medium molecular 
weight CIC — 4.5% PEG, low molecular weight CIC — 
6% PEG [31].
For comparison of immunological parameters 
of animals from experimental and control groups 
modulation index (MIec) for each EC type was calcu-
lated as follows [32]:
MIec = [CTAIe (ν) – CTAIe (µν)/CTAIe (µν)] • 100%,
where CTAIec (v) — index CTAIec for the group 
of vaccinated animals; CTAIec (uv) — index CTAIec for 
the group of unvaccinated animals.
At late terms of observation (32nd and 37th days after 
the surgery) Pearson correlation between MIec from 
vaccinated tumor bearing mice and corresponding 
metastatic parameters (number and volume of lung 
metastases) was carried out. Statistical analysis 
of the data was performed using Student’s t-criterion 
(StatSoft STATISTICA 7.0). Values p < 0.05 were con-
sidered statistically significant [33, 34].
RESULTS AND DISCUSSION
In Table 1 there are shown the results of determina-
tion of CIC levels in SB of intact animals and unvac-
cinated or vaccinated mice with surgically removed 
melanoma B-16. At 18th and 32rd days after the surgery 
the level of medium molecular weight CIC in unvac-
cinated experimental animals was 1.5 times higher 
than that of intact control. This fact is important as far 
as it is known that accumulation of immune complexes 
of low and medium molecular weight capable to bind 
complement in SB, promotes the development of in-
flammation and results in negative influence on an or-
ganism. It is necessary to note also that increased 
level of medium molecular weight CIC in SB evidences 
on increase of endogenous intoxication level and 
serves as unfavorable prognostic index in cancer 
patients [35, 36].
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Table 1. Level of CIC in blood serum of intact, vaccinated and unvac-
cinated mice
Animals group
Mean CIC, c.u.
High molecular 
weight
Medium 
molecular weight
Low molecular 
weight
Intact 4.3 ± 2.3 18.7 ± 2.4 44.3 ± 10.9
22nd day after tumor transplantation/4th day after the surgery (before vaccination)
Unvaccinated 6.0 ± 4.0 17.5 ± 5.5 48.5 ± 3.5
36th day after tumor transplantation/18th day after the surgery
Unvaccinated 5.5 ± 0.5 28.5 ± 2.51 56.0 ± 10.0
Vaccinated 1.0 ± 0.11 19.5 ± 2.22 41.0 ± 1.0
51st day after tumor transplantation/32nd day after the surgery
Unvaccinated 7.0 ± 3.0 29.5 ± 2.31 68.5 ± 12.5
Vaccinated 8.0 ± 3.4 22.5 ± 1.52 49.5 ± 13.5
Note: 1р < 0.05 compared to intact control; 2р < 0.05 compared to unvac-
cinated animals.
The study of weight and cellularity indexes of im-
munocompetent organs (spleen, thymus, peripheral 
lymph nodes) and liver in unvaccinated mice with 
surgically removed melanoma B-16 has revealed 
significant increase (р < 0.05) of relative weight 
of spleen and liver, and also total cellularity of spleen 
compared to intact animals (Table 2). Such changes 
have been observed during all observation period 
evidencing on negative influence of residual tumor 
disease on the organisms of the mice. In vaccinated 
animals these indexes remained at the level of those 
in intact animals till 37th day after the surgery and were 
significantly lower than these in unvaccinated mice 
at late terms of observation. Relative weight of liver 
in vaccinated animals was also significantly lower than 
in unvaccinated mice but was higher than that in intact 
group (see Table 2). So, the use of XCV prevented 
an increase of spleen weight and cellularity.
The results of the study of CTA of effectors of spe-
cific and unspecific chains of immune system are 
presented on Figure. NK CTA of unvaccinated mice 
with surgically removed melanoma B-16 significantly 
decreased at 4th day after the surgery compared 
with intact control (10.5 ±1.4% vs 19.5 ± 1.7%; 
р < 0.05, respectively), at later terms this index came 
close to the level of intact animals. At conditions 
of vaccination there was observed significant increase 
of CTAI compared with intact mice as well as unvac-
cinated animals with surgically removed melanoma 
B-16 during all observation period (Figure, a). Activity 
of specific cytotoxic lymphocytes in unvaccinated 
mice compared with intact animals significantly de-
creased at 32nd day after surgical removal of melanoma 
(15.2 ± 0.4 and 27.7 ± 1.2%, respectively; р < 0.05). 
Administration of the vaccine to mice with surgically 
removed melanoma B-16 led to normalization of this 
index at the late terms of tumor development (Figure, b).
Also, the use of XCV demonstrated an activating 
effect on PM chain of immunity. This is evidenced 
by an increase of PM counts in vaccinated mice com-
pared with intact and unvaccinated mice with surgically 
removed melanoma B-16, especially at 32th day after the 
surgery (by 2.1 times; р < 0.05) and elevation of their 
CTAI against melanoma В-16 cells (Table 3).
As it is shown in Table 4, starting from 18th day 
after surgical removal of melanoma, in vaccinated 
mice there has been registered significant increase 
of CTA of SB (р < 0.05), as well as its potentiating ef-
fect on PM activity.
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Figure. CTAI of spleen lymphocytes (a — NK, b — CTL) in intact, 
vaccinated and unvaccinated С57Bl mice (*р < 0.05 compared 
to intact control; **р < 0.05 compared to unvaccinated animals)
Table 2. Weight and cellularity of immunocompetent organs and liver of vaccinated and unvaccinated mice treated by surgery removal of В-16 melanoma
Animals group Animal weight, g
Relative organ weight (× 10–3) Cellularity per 1 mg of organ
Spleen Thymus Peripheral lymph nodes Liver Spleen Thymus
Peripheral 
lymph nodes
Intact 
(n = 10)
21.3 ± 0.8 
(19.9–24.4)
4.6 ± 0.6 
(3.6–6.8)
1.1 ± 0.2 
(0.6–1.8)
2.8 ± 0.4 
(2.1–4.0)
56.8 ± 0.7 
(53.4–58.0)
1.3 ± 0.1 
(1.03–1.64)
2.7 ± 0.4 
(1.63–3.73)
1.6 ± 0.2 
(1.06–1.97)
22nd day after tumor transplantation/4th day after the surgery 
(before vaccination)
Unvaccinated (n = 5) 18.4 ± 0.81 8.5 ± 1.21 1.0 ± 0.2 2.8 ± 0.3 60.4 ± 2.0 1.2 ± 0.2 2.5 ± 0.3 1.8 ± 0.2
36th day after tumor transplantation/18th day after the surgery
Unvaccinated (n = 5) 21.1 ± 1.0 8.5 ± 1.31 1.1 ± 0.2 2.9 ± 0.2 84.7 ± 3.91 1.0 ± 0.01 2.7 ± 0.4 1.1 ± 0.0
Vaccinated (n = 5) 21.7 ± 0.7 8.2 ± 1.9 1.1 ± 0.0 3.0 ± 0.2 64.2 ± 1.71,2 1.1 ± 0.1 2.4 ± 0.2 1.3 ± 0.1
51st day after tumor transplantation/32nd day after the surgery
Unvaccinated (n = 5) 22.2 ± 0.7 7.9 ± 0.41 1.3 ± 0.2 3.2 ± 0.5 71.9 ± 2.01 1.1 ± 0.1 2.2 ± 0.2 1.7 ± 0.2
Vaccinated (n = 5) 22.1 ± 0.5 6.1 ± 0.42 1.5 ± 0.2 3.4 ± 0.3) 64.0 ± 2.71 1.1 ± 0.1 2.5 ± 0.2 1.7 ± 0.1
56th day after tumor transplantation / 37th day after the surgery
Unvaccinated (n = 5) 16.8 ± 1.01 14.7 ± 1.51 1.7 ± 0.8 3.6 ± 1.8 71.9 ± 3.81 0.5 ± 0.11 3.8 ± 1.0 0.6 ± 0.11
Vaccinated (n = 5) 16.2 ± 0.91 9.2 ± 1.11,2 0.8 ± 0.2 2.6 ± 0.5 49.2 ± 0.31,2 1.2 ± 0.12 1.1 ± 0.21,2 0.7 ± 0.11
Note: 1р < 0.05 compared to intact control; 2р < 0.05 compared to unvaccinated animals.
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Table 3. Effect of XCV on PM in intact, vaccinated and unvaccinated С57Bl mice
Animals group Cellularity of PM (×106) CTAI of PM, %
Intact 3.9 ± 0.2 (3.2–4.8) 31.4 ± 2.7(20.8–41.2)
22nd day after tumor transplantation/4th day after the surgery 
(before vaccination)
Unvaccinated 2.9 ± 0.4 13.7 ± 3.41
36th day after tumor transplantation/18th day after the surgery
Unvaccinated 2.5 ± 0.51 16.6 ± 2.81
Vaccinated* 5.5 ± 0.82 35.4 ± 3.12 (113.3)
51st day after tumor transplantation/32nd day after the surgery
Unvaccinated 3.9 ± 0.8 35.6 ± 2.3
Vaccinated* 8.2 ± 1.21,2 32.1 ± 1.9 (−9.8)
56th day after tumor transplantation/37th day after the surgery
Unvaccinated 3.2 ± 0.7 32.0 ± 0.9
Vaccinated* 5.0 ± 0.5 37.3 ± 0.62 (16.6)
Note: *given in brackets MIec compared to unvaccinated animals; 1р < 0.05 com-
pared to intact control; 2р < 0.05 compared to unvaccinated animals.
Table 4. Effect of SB of intact and treated by surgery removal of В-16 mela-
noma С57Bl/6 mice on CTA of lymphocytes (CTL) and PM
Animals group CTAI of SB, % ADCC of:CTL (CTAI, %) PM (CTAI, %)
Intact 6.5 ± 1.8 
(6.1–18.6)
29.4 ± 2.4
 (18.8–40.3)
27.6 ± 2.4  
(16.9–44.2)
22nd day after tumor transplantation/4th day after the surgery 
(before vaccination)
Unvaccinated 2.2 ± 0.9 27.6 ± 2.9 11.6 ± 3.71
36th day after tumor transplantation/18th day after the surgery
Unvaccinated 11.6 ± 5.8 36.8 ± 3.2 24.3 ± 2.1
Vaccinated* 20.5 ± 4.01 (76.7) 28.3 ± 1.6 (−23.1) 30.4 ± 2.0 (25.1)
51st day after tumor transplantation/32rd day after the surgery
Unvaccinated 19.7 ± 2.91 14.2 ± 4.11 29.4 ± 1.5
Vaccinated* 19.5 ± 7.0 (−1.1) 31.9 ± 1.92 (124.6) 36.1 ± 2.92 (22.8)
56th day after tumor transplantation/37th day after the surgery
Unvaccinated 15.4 ± 2.8 30.2 ± 6.4 37.0 ± 1.2
Vaccinated* 31.1 ± 3.21,2 (101.9) 32.9 ± 2.2 (8.9) 43.1 ± 1.71,2 (16.5)
Note: *given in brackets MIec compared to unvaccinated animals; 1р < 0.05 com-
pared to intact control; 2р < 0.05 compared to unvaccinated animals.
These data showed that administration of the vaccine 
to mice with surgically removed melanoma B-16 pro-
vided preservation (or elevation) of CTA of effectors 
of cellular anticancer immunity and CTA of SB at the 
late terms after the surgery, i.e., at the period of intense 
metastasis. This fact, possibly, could explain significant 
decrease of the number and volume of metastases 
in vaccinated animals reported earlier by us [25].
To test this assumption, we have calculated cor-
relation indexes between the indexes characterizing 
tumor development (the quantity and volume of me-
tastases) after surgical removal of the primary tumors 
and the abovementioned indexes of activity of cellular 
anticancer immunity effectors and SB of experimental 
animals. There has been performed an evaluation 
of the strength relationship between these indexes 
and correlation coefficient r by Chaddock’s scale [34].
The negative correlation of modulation of the majority 
of the studied parameters with lung metastasis numbers 
and volumes has been revealed (Table 5). At 32nd day 
after the surgery (51st day of tumor development) there 
has been registered the negative correlation between 
CTA of NK and metastasis numbers (strong; r = −0.96; 
р < 0.05) and volumes (good; r = −0.68). At 37th day 
after the surgery (56th day of tumor development) 
the correlation between these indexes was strongly 
negative (r = −0.88; р < 0.05 and r = −0.95; р < 0.05, 
respectively). Correlation relationship between metas-
tasis indexes and PM CTA remained strongly negative 
at 32nd (р < 0.05) and 37th days after tumor removal. 
Correlation between CTL CTA and the quantity of me-
tastases increased from moderate (r = −0.33) to strong 
(r = −0.84), and with metastases volumes — from very 
weak (r = −0.16) to strong (r = −0.88; р < 0.05). Also 
there were registered the changes of correlation rela-
tionship between metastasis indexes and SB CTA (from 
weak to good), antibody-dependent cell cytotoxicity 
(ADCC) of CTL (from weak to moderate) and ADCC 
of PM (from good to strong).
These data allow suppose that antimetastatic ef-
fect of the developed XCV is caused by the increase 
of CTA of NK and PM and also by preservation of CTL 
functional activity at the late terms after the surgery. 
Therefore, the mechanism of action of the vaccine 
is somewhat different from that of xenogeneic 
anticancer vaccines developed by Russian scientists 
on the basis of melanoma cells. Anticancer activity 
of Russian vaccines is mainly exerted via activation 
of specific chain of immunity due to the presence 
of specific melanoma antigens. In particular, has 
shown the development of prolonged anticancer re-
sponse in mice with melanoma В-16 vaccinated with 
human melanoma cells SK-MEL-1 at the background 
of increased CTL activity. Activation of specific chain 
of cell immunity has been also documented in clinical 
studies when the patients with uveal melanoma were 
vaccinated with xenogeneic vaccine containing mouse 
melanoma В-16 cells transplanted into conjunctive 
tissue capsule [17, 18], or when the patients with meta-
static skin melanoma were vaccinated with polyantigen 
cellular vaccine on the basis of В-16 melanoma cells 
and mouse Lewis lung carcinoma cells [16].
Table 5. Correlation (r) between the MI of CTA of EC from vaccinated C57Bl 
mice and metastatic parameters
MI of CTA 
of EC
Metastatic parameters
Number of lungs metastases Volume of metastases
32nd after 
the surgery
37th after 
the surgery
32nd after 
the surgery
37th after 
the surgery
NK −0.96* −0.88* −0.68 −0.95*
CTL −0.33 −0.84 −0.16 −0.88*
PM −0.86* −0.77 −0.75 −0.76
SB −0.47 −0.70 −0.22 −0.57
ADCC of CTL 0.04 0.26 −0.12 0.31
ADCC of PM −0.68 −0.50 −0.62 −0.91*
Note: *р < 0.05.
Antimetastatic efficacy of xenogeneic anticancer 
vaccine developed on the basis of embryonal proteins 
and products of bacterial origin (B. subtilis) is mostly 
exerted via activation of effectors of unspecific im-
munity (PM and NK). Increase of SB CTA against 
В-16 melanoma cells in vaccinated animals and its 
potentiating influence on PM could possibly evidence 
on appearance of some cytokines (in particular, inter-
leukine 1, interferon-gamma (IFN-γ), tumor necrosis 
factor) in circulation, which provide activation of un-
specific immunity as well as preservation of specific im-
mune response at the level of intact animals. It is known 
that a special role in realization of anticancer response 
is played by IFN-γ produced by T-lymphocytes, NK 
(upon their contact with TC), and activated PM. This 
cytokine shows significant immunomodulating action 
via its influence on practically all EC of immune sys-
tem [37]. If consider the data on interferonogenic ac-
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tivity of the products of B. subtilis [38], the metabolites 
of which were used for the construction of this vaccine 
one may suppose that IFN-γ and other cytokines may 
play a role in anticancer effect of the XCV. However, 
such hypothesis requires further studies.
REFERENCES
1. Cancer in Ukraine, 2012–2013. Incidence, mortality, 
performance level of cancer care service. Bull Natl Cancer 
Register in Ukraine № 15. Kyiv, 2014: 13, 41–2 (in Ukrainian).
2. Monzon JG, Dancey J. Target agents for the treatment 
of metastatic melanoma. Onco Targets Ther 2012; 5: 31–46.
3. Fil’chakov FV, Korovin SI. Modern approaches to adop-
tive immunotherapy of metastatic skin melanoma patients. 
Klin Onkol 2012; 6: 124–8 (in Russian).
4. Agarwala SS. Novel immunotherapies as potential 
therapeutic partners for traditional or targeted agents: cytotoxic 
T-lymphocyte antigen-4 blockade in advanced melanoma. 
Melanoma Res 2010; 20: 1–10.
5. Verdegaal EM, Visser M, Ramwadhdoebe TH, et al. 
Successful treatment of metastatic melanoma by adoptive 
transfer of blood-derived polyclonal tumor-specific CD4+ and 
CD8+ T-cells in combination with low-dose interferon-alpha. 
Cancer Immunol Immunother 2011; 60: 953–63.
6. Besser MJ, Shapira-Frommer R, Treves AJ, et al. 
Clinical responses in a phase II study using adoptive transfer 
of short-term cultured tumor infiltration lymphocytes in meta-
static melanoma patients. Clin Cancer Res 2010; 16: 2646–55.
7. Chiang CL, Benencia F, Coucos G. Whole tumor an-
tigen vaccines. Semin Immunol 2010; 22: 132–43.
8. Mikhailova TV, Baryshnikova MA, Klimenko OV, 
et al. Development of liposomal form of cancer vaccine. Ross 
Biotherapeut Zh 2011; 10: 62–6 (in Russian).
9. Mikhailova IN, Mikhailova LM, Abramova TV, et al. 
Preclinical studies of toxicity of cancer vaccine "Melavac". 
Ross Biother Zh 2010; 1: 57–62 (in Russian).
10. Graf N, Adam C, Mocikat R. Persistence of xeno-
genized vaccine cells in vivo. Int J Cancer 2003; 105: 217–20.
11. Bergman PJ, Wolchok JD. Of mice and men (and 
dogs): development of a xenogeneic DNA vaccine for canine 
oral malignant melanoma. Cancer Ther 2008; 6: 817–26.
12. Seledtsov VI, Seledtsova GV. Xenovaccinotherapy 
in cancer. Sib Zh Cancer 2010; (3): 48–57 (in Russian).
13. Steitz J, Bruck J, Steinbrink K, et al. Genetic immu-
nization of mice with human tyrosinase-related protein 2: im-
plications for the immunotherapy of melanoma. Int J Cancer 
2000; 86: 89–94.
14. Vollmers H, Birchmeier W. Monoclonal antibodies 
that prevent adhesion of B-16 melanoma cells and reduce 
metastasis in mice: cross-reaction with human tumor cells. 
Proc Natl Acad Sci USA 1983; 80: 6863–7.
15. Barannikova TV. Skin and uveal melanoma: methods of the-
rapy and prophylaxis of metastasis (review) (http://vestnik.rncrr.ru/ 
vestnik/v11/barannikova_v11.htm) (in Russian).
16. Seledtsov VI, Shishkov AA, Surovtseva MA, et al. 
Xenovaccinotherapy for melanoma. Eur J Dermatol 2006; 
16: 655–61.
17. Chissov VI, Sergeeva NS, Severin SE, et al. Develop-
ment of the method for antitumor vaccination of mice into pre-
viously incapsulated polyacrylamide gel on the model of mouse 
melanoma В-16. Mol Med 2004; 2: 24–8 (in Russian).
18. Moskaleva EYu, Rodina AV, Gusakova NV, et al. 
Induction of melanoma-specific response in mice after xeno-
geneic vaccination with human melanoma cells injected into 
previously subcutaneously incapsulated polyacrylamide gel. 
Immunokhimiya 2000; 6: 329–36 (in Russian).
19. Berinstein NL. Enhancing cancer vaccines with im-
munomodulators. Vaccine 2007; 25: 72–88.
20. Luo Y, Wen YJ, Ding ZY, et al. Immunotherapy 
of tumors with protein vaccine based on chicken homologous 
Tie-2. Clin Cancer Res 2006; 12: 1813–9.
21. Seledtsov VI, Felde MA, Samarin DM, et al. Im-
munological and clinical aspects of applying xenovac-
cinotherapy in treating melanoma. Russian Oncol J 2006; 
(4): 23–9 (in Russian).
22. Kaschenko EA. Cellular and humoral mechanisms 
of tumor specific immunotherapy and their modulation under 
the influence of hyperthermia. Author Dis Cand Biol Sciences, 
Novosibirsk, 2009. 22 p. (in Russian).
23. Seledtsov VI, Niza NA, Surovtseva MA, et al. Xeno-
vaccinotherapy for colorectal cancer. Biomed Pharmacother 
2007; 61: 125–30.
24. Potebnya GP, Voeykova ІМ, Yudina OYu, et al. The 
way to generate cancer vaccine. Patent of Ukraine on useful 
model № 78756. 25.03.2013, Bull № 6 (in Ukrainian).
25. Voeykova ІМ, Fedosova NІ, Karaman ОМ, et al. Use 
of xenogeneic vaccine modified with embryonal nervous tissue 
antigens in the treatment of B16-melanoma-bearing mice. Exp 
Oncol 2014; 36: 24–8.
26. Kozhem’yakin YuM, Khromov OS, Filonenko 
MA, Sayfetdinova GA. Scientific-practical recommenda-
tions on animal care and laboratory use. Kyiv 2002, 179 p. 
(in Ukrainian).
27. Council Directive 2010/63/EU of 22 september 
2010 on the protection of animals used for scientific purposes. 
Official J Eur Commun 2010; L 276: 33–79.
28. Experimental evaluation of anticancer prepara-
tions in USSR and USA. ZP Sofyina, AV Syrkin, eds. Mos-
kow: Meditsina, 1980. 79 p. (in Russian).
29. Lymphocytes. Methods. J Klaus, ed. Moskow: Mir, 
1990. 395 p. (in Russian).
30. Mosmann T. Rapid colorimetric assay for cellular 
growth and survival: Application to proliferation and cytotoxi-
city assays. J Immunol Methods 1983; 65: 55–63.
31. Perederiy VG, Zemskov АМ, Bychkova NG, et al. Im-
mune status, principles of its evaluation and correction of im-
mune dysfunction. Kyiv: Zdorovya, 1995. 211 p. (in Russian).
32. Kovbasyuk SA, Yudin VM, Kravchenko SP. Immuno-
modulating influence of cyclophosphane in different schemes 
of its administration to mice. Tsitologiya 1985; (3): 316–
21 (in Russian).
33. Lakin GF. Biometry. Moskow: Vyschaya Shkola, 1980. 
290 p. (in Russian).
34. Sydenko AV, Vyshnyakov VV, Isaev SM. Theory of statis-
tics: manual. Moskow: MAKS-Press, 2011. 343 p. (in Russian).
35. Lysenko SA. Аnalysis of immunological indicators 
of blood in lung cancer patients with paraneoplastic rheumatic 
syndrome who have not received special anticancer treatment. 
Clin Exp Pathol 2013; 12: 109–113.
36. Soroka YuV, Demkiv IYa, Lisnychuk NYe. Мarkers 
of endogenic intoxication and state of immune system of white 
rats at chronic neoplastic intoxication. Tavrich Med-Biol 
Vestnik 2012; 15: 308–10 (in Russian).
37. Sologub TV, Ledvanov MYu, Maliy VP, et al. Immune 
response in viral infections. Uspekhi Sovrem Estestvozn 2009; 
12: 29–33 (in Russian).
38. Starovoitova SA, Skroitskaya OI. Probiotics on the ba-
sis of transgenic microorganisms. Biotechnologia Acta 2013; 
6: 34–45 (in Russian).
 Copyright © Experimental Oncology, 2015 
